

SYNTHESIS, CHARACTERIZATION OF NOVEL BENZOTHIOPHENE

Veerappan Jeyachandran

Department of Chemistry, Bharath Institute of Higher Education and Research, Selaiyur, Chennai-600073,
Tamil Nadu, India.

jeyorg@gmail.com

Abstract

A library of novel benzo[*b*]thiophene have been synthesized regioselectively in good yields through the one-pot domino reactions of thiophenone, malononitrile and aromatic aldehydes in the presence of NaOEt. This transformation presumably involves Knoevenagel condensation–Michael addition–intramolecular Thorpe–Ziegler cyclization–Tautomerization–Elimination sequence of reactions.

Introduction

benzo[*b*]thiophene derivatives are found within the structural core of several biologically active compounds, for example, raloxifeneTM is a selective estrogen receptor modulator for the prevention of osteoporosis in postmenopausal women¹ and zileutonTM is an active inhibitor of 5-lipoxygenase used to prevent difficulty in breathing, wheezing and coughing due to asthma and sertaconazole has several known mechanisms of action (Figure 1).²




Figure 1. Benzo[*b*]thiophene derivatives synthesized in the present work

Other pharmacological applications of benzo[*b*]thiophene derivatives include estrogen receptor antagonists,³ antifungal,⁴ antiinflammatory⁵ and antimetotic⁶ agents. The above significance of benzo[*b*]thiophene derivatives has set path to several investigations leading to their synthesis and biological activity studies.⁷

Several other molecular entities containing benzothiophene core are at various stages of development. They include **T588**⁸ a cognition enhancing agent with potential application for treating Alzheimer's dementia; **LY353381**⁹ an additional SERM from Lilly; **AP521**¹⁰ with potent 5Ht_{1A} receptor binding ability; **CI959**¹¹ an anti-inflammatory agent; and **B428**¹² a urokinase inhibitor. Another structurally interesting compound is **PD144795**¹³ an endothelial cell activation inhibitor as a benzothiophene oxide (Figure 3).





Figure 3. Benzothiophenes Various stages of development

In view of the importance of benzothiophene derivatives, herein we report a domino protocol for the regioselective synthesis of a library of highly functionalized novel 5-amino-2,7-diaryl-2,3-dihydrobenzo[*b*]thiophene-4,6-dicarbonitriles **4** in good yields through the one-pot four-component reactions of 5-aryldihydro-3(2*H*)-thiophenones **1**, malononitrile **2** and aromatic aldehydes **3** in the presence of morpholine (Scheme 1).



Scheme 1. Synthesis of 2,3-dihydrobenzo[*b*]thiophene-4,6-dicarbonitriles **4**

Structure elucidation

The structure of all the Benzo[*b*]thiophenes **4** were elucidated unambiguously with the help of one and two-dimensional NMR spectroscopy. As a representative case, the ¹H and ¹³C NMR chemical shift assignment of **4r** are discussed.

In the ¹H NMR spectra of **4r**, the 2-CH and the 5-NH₂ protons overlap and appear as a multiplet at 5.01–5.08 ppm. The D₂O exchange experiment reveals that the H-2 appears as a triplet at 5.04 ppm (*J* = 8.4 Hz) and the latter appears as a broad singlet at 5.08 ppm.

Table 2. Yield and melting point of Benzo[b]thiophene **4**

Entry	Comp	Ar'	Yield of 4 (%)	mp (°C)
1	4a	4-MeC ₆ H ₄	79	165-167
2	4b	4-MeOC ₆ H ₄	85	167-169
3	4c	4-ClC ₆ H ₄	72	175-177
4	4d	4-FC ₆ H ₄	73	157-1159

^a Isolated yield after purification by column chromatography

Conclusions

The present investigation reports a one-pot domino protocol for the regioselective synthesis of novel Benzo[b]thiophene via Knoevenagel condensation–Michael addition–intramolecular Thorpe-Ziegler cyclization–Tautomerization–Elimination sequence of reactions.

This four-component reaction results in the formation of four new C–C bonds in a single operation. The structure of all the Benzo[b]thiophene was elucidated with NMR and single crystal X-ray studies.

References

1. Marketed as Evista® (Raloxifene Hydrochloride 60 mg). Grese, T.A.; Dodge, J. A.; Curr. Pharm. Des., 1998, 4, 71.
2. Carter, G. W.; Young, P. R.; Albert, D. H.; Bouska, J.; Dyer, R.; Bell, R. L.; Summers, J. B.; Brooks, D. W. J. Pharmacol. Exp. Ther., 1991, 256, 929.
3. (a) Palkowitz, A. D.; Glasebrook, A. L.; Thrasher, K. J.; Hauser, K. L.; Short, L. L.; Phillips, D. L.; Muehl, B. S.; Sato, M.; Shetler, P. K.; Cullinan, G. J.; Pell, T. R.; Bryant, H. U. J. Med. Chem., 1997, 40, 1407; (b) Magarian, R. A.; Overacre, L. B.; Singh, S.; Meyer, K. L. Curr. Med. Chem., 1994, 1, 61.
4. Thesen, R. Pharm. Ztg., 1995, 140, 44.
5. Bleavins, M. R.; Igelsia, F. A.; McCay, J. A.; White, L.; Kimber, L.; Munson, A. E. Toxicology, 1995, 98, 111.
6. Zhang, S. X.; Bastow, K. F.; Tachibana, Y.; Kuo, S. C.; Hamel, E.; Mauger, A.; Narayanan, V. L.; Lee, K.H. J. Med. Chem., 1999, 42, 4081.
7. (a) Shedid, S. A. M.; Hassan, H. M.; Kora, F. A.; El-Eisawy, R. M. J. Chem. Pharm. Res., 2011, 3, 388; (b) Isloor, A. M.; Kalluraya, B.; Sridhar, P. K. Eur. J. Med. Chem., 2010, 45, 825; (c) Radwan, M. A. A.; Shehab, M. A.; El-Shenawy, S. M. Monatsh Chem., 2009, 140, 445
8. Ono, S.; Yamafuji, T.; Chaki, H.; Todo, Y.; Maekawa, M.; Kitamura, K.; Kimura, T.; Nakada, Y.; Mozumi, K.; Narita, H. Biol. Pharm. Bull., 1995, 18, 1779–1783.
9. Sato, M.; Turner, C. H.; Wang, T.; Adrian, M. D.; Rowley, E.; Bryant, H. U. J. Pharmacol. Exp. Ther., 1998, 287, 1–7.
10. Sorbera, L. A.; Leeson, P.; Castaner, J. Drugs Fut., 1999, 24, 740.

11. Wright, C. D.; Stewart, S. F.; Kuipers, P. J.; Hoffman, M. D.; Devall, L. J.; Kennedy, J. A.; Ferin, M. A.; Thueson, D. O.; Conroy, M. C. J. *Leukoc. Biol.*, 1994, 55, 443–451.
12. Towle, M. J.; Lee, A.; Maduakor, E. C.; Schwartz, C. E.; Bridges, A. J.; Littlefield, B. A. *Cancer Res.*, 1993, 53, 2553–2559.
13. Carballo, M.; Conde, M.; Tejedo, J.; Gualberto, A.; Jimenez, J.; Monteseirín, J.; Santa María, C.; Bedoya, F. J.; Hunt, S. W. 3rd.; Pintado, E.; Baldwin, A. S. Jr.; Sobrino, Fr. *Mol. Genet. Metab.*, 2002, 75, 360–368.